Tobira Therapeutics Inc. (NASDAQ:TBRA) major shareholder Pentwater Capital Management L bought 40,000 shares of the stock in a transaction that occurred on Tuesday, October 18th. The stock was bought at an average cost of $40.06 per share, for a total transaction of $1,602,400.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Pentwater Capital Management L also recently made the following trade(s):

  • On Tuesday, October 4th, Pentwater Capital Management L bought 4,481 shares of Tobira Therapeutics stock. The stock was bought at an average cost of $39.83 per share, for a total transaction of $178,478.23.
  • On Thursday, September 29th, Pentwater Capital Management L bought 15,519 shares of Tobira Therapeutics stock. The stock was bought at an average cost of $39.49 per share, for a total transaction of $612,845.31.
  • On Monday, September 26th, Pentwater Capital Management L bought 50,000 shares of Tobira Therapeutics stock. The stock was bought at an average cost of $39.00 per share, for a total transaction of $1,950,000.00.
  • On Friday, September 23rd, Pentwater Capital Management L bought 100,000 shares of Tobira Therapeutics stock. The stock was bought at an average cost of $39.19 per share, for a total transaction of $3,919,000.00.
  • On Thursday, September 22nd, Pentwater Capital Management L bought 1,624,200 shares of Tobira Therapeutics stock. The stock was bought at an average cost of $39.04 per share, for a total transaction of $63,408,768.00.

Shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) traded up 0.32% during midday trading on Wednesday, hitting $40.41. The stock had a trading volume of 89,143 shares. The company’s market cap is $760.56 million. The stock’s 50-day moving average price is $25.84 and its 200 day moving average price is $12.84. Tobira Therapeutics Inc. has a 52 week low of $3.76 and a 52 week high of $41.39.

Tobira Therapeutics (NASDAQ:TBRA) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.08. The firm had revenue of $1.06 million for the quarter. On average, equities analysts forecast that Tobira Therapeutics Inc. will post ($2.65) earnings per share for the current year.

Insider Buying and Selling by Quarter for Tobira Therapeutics (NASDAQ:TBRA)

TBRA has been the topic of a number of recent research reports. Zacks Investment Research raised Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Friday, July 29th. Cowen and Company reaffirmed a “buy” rating and issued a $11.00 target price on shares of Tobira Therapeutics in a research report on Wednesday, August 10th. Cantor Fitzgerald downgraded Tobira Therapeutics to a “buy” rating and set a $19.00 price target on the stock. in a research report on Monday, July 25th. HC Wainwright reissued a “buy” rating and set a $31.00 price target (up previously from $22.00) on shares of Tobira Therapeutics in a research report on Saturday, August 13th. Finally, Mizuho reissued a “buy” rating and set a $305.00 price target on shares of Tobira Therapeutics in a research report on Thursday, September 22nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Tobira Therapeutics currently has an average rating of “Buy” and a consensus target price of $68.63.

Several institutional investors have recently added to or reduced their stakes in the company. Havens Advisors LLC bought a new position in Tobira Therapeutics during the third quarter worth about $119,000. Schwab Charles Investment Management Inc. bought a new position in Tobira Therapeutics during the second quarter worth about $177,000. Teachers Advisors Inc. boosted its position in Tobira Therapeutics by 287.1% in the second quarter. Teachers Advisors Inc. now owns 14,484 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 10,742 shares during the period. California State Teachers Retirement System boosted its position in Tobira Therapeutics by 230.2% in the second quarter. California State Teachers Retirement System now owns 18,578 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 12,951 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in Tobira Therapeutics during the second quarter worth about $263,000. 62.41% of the stock is currently owned by institutional investors.

Tobira Therapeutics Company Profile

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

5 Day Chart for NASDAQ:TBRA

Receive News & Stock Ratings for Tobira Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Therapeutics Inc. and related stocks with our FREE daily email newsletter.